# Study of TJ011133 in Participants With Relapsed/Refractory Advanced Solid Tumors and Lymphoma

> **NCT03934814** · PHASE1 · COMPLETED · sponsor: **I-Mab Biopharma US Limited** · enrollment: 98 (actual)

## Conditions studied

- Solid Tumor
- Lymphoma

## Interventions

- **DRUG:** TJ011133
- **DRUG:** Pembrolizumab
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT03934814
- **Lead sponsor:** I-Mab Biopharma US Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-04-16
- **Primary completion:** 2023-01-10
- **Final completion:** 2023-01-10
- **Target enrollment:** 98 (ACTUAL)
- **Last updated:** 2024-07-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03934814

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03934814, "Study of TJ011133 in Participants With Relapsed/Refractory Advanced Solid Tumors and Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03934814. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*